Based in Chapel Hill, North Carolina, Select ImmunoGenomics specializes in data analysis, predictive modeling, and reporting for genomic studies. The company's services are designed to support the development of immuno-oncology drugs by providing advanced immunogenomic and biomarker development services. With a focus on precision medicine, Select ImmunoGenomics offers a range of solutions to help researchers and drug developers better understand the complex interactions between the immune system and cancer cells. Whether it's identifying new targets for drug development or optimizing existing therapies, Select ImmunoGenomics is committed to helping its clients achieve their goals in the fight against cancer.